摘要 : Non-alcoholic fatty liver disease(NAFLD),characterized by hepatic steatosis,is a common metabolic liver disease worldwide.Currently,satisfactory drugs for NAFLD treatment remain lacking.Obesity and diabetes are the leading causes ... 展开 Non-alcoholic fatty liver disease(NAFLD),characterized by hepatic steatosis,is a common metabolic liver disease worldwide.Currently,satisfactory drugs for NAFLD treatment remain lacking.Obesity and diabetes are the leading causes of NAFLD,and compounds with anti-obesity and antidiabetic activities are considered suitable candidates for treating NAFLD.In this study,biochemical and histological assays revealed that a natural lignan schisanhenol(SAL)effectively decreased lipid accumulation and improved hepatic steatosis in free fatty acid(FFA)-treated HepG2 cells and high-fat diet(HFD)-induced NAFLD mice.Further,molecular analyses,microRNA(miRNA)-seq,and bioinformatics analyses revealed that SAL may improve NAFLD by targeting the miR-802/adenosine monophosphateactivated protein kinase(AMPK)pathway.Liver-specific overexpression of miR-802 in NAFLD mice significantly impaired SAL-mediated liver protection and decreased the protein levels of phosphorylated(p)-AMPK and PRKAB1.Dual-luciferase assay analysis further confirmed that miR-802 inhibits hepatic AMPK expression by binding to the 3’untranslated region of mouse Prkab1 or human PRKAA1. 收起